Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Protagenic Therapeutics, Inc.\new

CIK 1022899 PTIX·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Late filing NT 10-Q
  2. Finance chief departure 8-K +48d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Late filing Filing comparison

Protagenic Therapeutics, Inc.\new told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed on the statutory due date.

(the “Company”) will not be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 by the prescribed due date without unreasonable effort or expense.
Evidence
Anticipates significant change
No
Days past due date
0
Other periodic reports filed
Yes
Routine
Yes
Severity
normal
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) will not be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 by the prescribed due date without unreasonable effort or expense.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Late filing elevated Filing comparison

Protagenic Therapeutics, Inc.\new told the SEC it could not file its annual report on time

Does not expect a significant change in results. 1 day past the statutory due date.

During the fiscal year, the Company entered into a business combination transaction requiring the application of complex accounting guidance, accounting, and related financial reporting considerations. Management and the Company’s independent registered public accounting firm require additional time to complete their evaluation of these matters, finalize the Company’s financial statements, complete required audit procedures, and complete the review of the related disclosures. These forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results or the timing of events…
Evidence
Anticipates significant change
No
Days past due date
1
Other periodic reports filed
Yes
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
During the fiscal year, the Company entered into a business combination transaction requiring the application of complex accounting guidance, accounting, and related financial reporting considerations. Management and the Company’s independent registered public accounting firm require additional time to complete their evaluation of these matters, finalize the Company’s financial statements, complete required audit procedures, and complete the review of the related disclosures. These forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results or the timing of events…
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Finance chief departure Filing comparison

Protagenic Therapeutics, Inc.\new's Chief Financial Officer departed and a successor was named

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
normal
Source
SEC 8-K item code
Successor named
Yes
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Late filing Filing comparison

Protagenic Therapeutics, Inc.\new told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. 4 days past the statutory due date.

(the “Company”) will not be able to file its Quarterly Report on Form 10-Q for the period ended December 31, 2025 by the prescribed due date without unreasonable effort or expense.
Evidence
Anticipates significant change
No
Days past due date
4
Other periodic reports filed
Yes
Routine
No
Severity
normal
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) will not be able to file its Quarterly Report on Form 10-Q for the period ended December 31, 2025 by the prescribed due date without unreasonable effort or expense.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗